Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Fox, Robert J
Miller, David H
Phillips, J Theodore
Dawson, Katherine T
Affiliation1. St. Vincent’s University Hospital, Elm Park, Donnybrook, Dublin 4, Ireland 2. The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA 3. NMR Research Unit, Department of Neuroinflammation, UCL Institute of Neurology, London, UK 4. Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX, USA 6. Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic 7. Biogen Idec Inc., Weston, MA, USA
Dose-Response Relationship, Drug
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting
MetadataShow full item record
CitationHutchinson M et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. 2013, 260 (9):2286-96 J. Neurol.
JournalJournal of neurology
AbstractIn the phase 3, randomized, placebo-controlled and active reference (glatiramer acetate) comparator CONFIRM study in patients with relapsing-remitting multiple sclerosis, oral BG-12 (dimethyl fumarate) reduced the annualized relapse rate (ARR; primary endpoint), as well as the proportion of patients relapsed, magnetic resonance imaging lesion activity, and confirmed disability progression, compared with placebo. We investigated the clinical efficacy of BG-12 240 mg twice daily (BID) and three times daily (TID) in patient subgroups stratified according to baseline demographic and disease characteristics including gender, age, relapse history, McDonald criteria, treatment history, Expanded Disability Status Scale score, T2 lesion volume, and gadolinium-enhancing lesions. BG-12 treatment demonstrated generally consistent benefits on relapse-related outcomes across patient subgroups, reflecting the positive findings in the overall CONFIRM study population. Treatment with BG-12 BID and TID reduced the ARR and the proportion of patients relapsed at 2 years compared with placebo in all subgroups analyzed. Reductions in ARR with BG-12 BID versus placebo ranged from 34% [rate ratio 0.664 (95% confidence interval 0.422-1.043)] to 53% [0.466 (0.313-0.694)] and from 13% [0.870 (0.551-1.373)] to 67% [0.334 (0.226-0.493)] with BG-12 TID versus placebo. Treatment with glatiramer acetate reduced the ARR and the proportion of patients relapsed at 2 years compared with placebo in most patient subgroups. The results of these analyses indicate that treatment with BG-12 is effective on relapses across a broad range of patients with relapsing-remitting multiple sclerosis with varied demographic and disease characteristics.
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
- Authors: Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson KT
- Issue date: 2013 Sep
- Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
- Authors: Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
- Issue date: 2012 Sep 20
- Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
- Authors: Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ, DEFINE and CONFIRM study investigators.
- Issue date: 2015 Apr
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
- Authors: Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
- Issue date: 2012 Sep 20
- Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
- Authors: Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL
- Issue date: 2017 Aug